- Home
- ABSI vs EVMN Comparison
ABSI vs EVMN Comparison
Compare ABSI & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | EVMN |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 997.8M | 869.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABSI | EVMN |
|---|---|---|
| Price | $11.60 | $12.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $6.96 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 7.8M | 1.1M |
| Earning Date | 05-07-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,534,000.00 | N/A |
| Revenue This Year | $215.96 | N/A |
| Revenue Next Year | $319.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $12.65 |
| 52 Week High | $12.06 | $33.20 |
Technical Indicators
Market Signals| Indicator | ABSI | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 73.84 | 28.50 |
| Support Level | $2.76 | N/A |
| Resistance Level | N/A | $20.37 |
| Average True Range (ATR) | 1.05 | 1.75 |
| MACD | 0.34 | -0.98 |
| Stochastic Oscillator | 91.83 | 2.02 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.